VKTX
Viking Therapeutics, Inc.
Key Financials
Revenue
$0
NaN%
Shareholders' Equity
$639.1M
↓ 27.4%
EPS (Diluted)
$-3.19
↓ 215.8%
Total Liabilities
$76.7M
↑ 173.4%
Total Assets
$715.7M
↓ 21.2%
Cash & Equivalents
$165.8M
↑ 521.6%
Operating Cash Flow
$-278685000.00
↓ 217.4%
Operating Income
$-393342000
↓ 160.6%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 9/28/2026 | View on SEC |
| 424B5 | 9/25/2026 | View on SEC |
| 424B5 | 9/25/2026 | View on SEC |
| FWP | 9/24/2026 | View on SEC |
| 305B2 | 9/24/2026 | View on SEC |
| 424B5 | 9/23/2026 | View on SEC |
| 424B5 | 9/23/2026 | View on SEC |
| 8-K | 9/22/2026 | View on SEC |
| 4 | 8/7/2026 | View on SEC |
| 3 | 8/7/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | VKTX |
| Company Name | Viking Therapeutics, Inc. |
| CIK | 1607678 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 858-704-4660 |